Bris­tol-My­er's Op­di­vo teams up with In­fin­i­ty's last hope

Bris­tol-My­er’s Op­di­vo will team up with In­fin­i­ty Phar­ma­ceu­ti­cals’ last hope IPI-549 in a Phase I. In­fin­i­ty will run the check­point in­hibitor and PI3K-gam­ma in­hibitor com­bo along­side its cur­rent tri­al to the test the ef­fec­tive­ness of the IPI-549 alone, the part­ner­ship is look­ing to score some points on in­creased po­ten­cy for Op­di­vo. Af­ter the pos­i­tive da­ta swirled around IPI-549 at AACR, In­fin­i­ty’s strat­e­gy now in­volves push­ing the PI3k can­cer drug with the check­point in­hibitor.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER